A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.


Updates from The Motley Fool

Latest updates on Exelixis from Fool.com.  The Fool has written over 400 articles on Exelixis.
Why Exelixis Dropped Today

The company announced a disappointing clinical trial failure, which fortunately wasn't for its to...

Exelixis Reaccelerates Growth

An expanded approval has the biotech's cancer drug Cabometyx headed in the right direction.



Stock Performance

View Interactive EXEL Charts
Sponsored by

Key Data Points

Primary metrics and data points about Exelixis.
Current Price: $22.93
Prev Close: $24.05
Open: $24.06
Bid: $22.93
Ask: $23.19
Day's Range: $22.90 - $24.06
52wk Range: $13.42 - $31.79
Volume: 4,067,098
Avg Vol 4,423,054
Market Cap: $7B
P/E (ttm): 20.56
EPS (ttm): $1.17
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Exelixis.
CAPS Rating 5 out of 5
 
2505 Outperform
96 Underperform
CAPS All Stars
 
633 Outperform
20 Underperform

How do you think Exelixis will perform against the market?



You pick for Exelixis is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Michael M. Morrissey, CEO

64% Approve

Based on 25 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Exelixis.

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers